Citations

Showing 10 of 108135 citations.

A Brainstem Mass Lesion
Almeida, Natalia E. Castillo , Trejo‐Lopez, Jorge , Issa, Meltiady , Sampathkumar, Priya , Castillo, Natalia E , Trejo-Lopez, Jorge A, Sampathkumar, Priya

Mayo Clinic

Clinical Infectious Diseases | September 15, 2021 | Volume: 75 | Issue: 2 | Pages: 356-357

10.1093/cid/ciab786 | PMID 36007258 Get It

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
Silberstein, Stephen D. , Tassorelli, Cristina , Guo, Hua , Lu, Kaifeng , Dabruzzo, Brett , Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle , Trugman, Joel M. , Silberstein, Stephan D , Tassorelli, Cristina , Schwedt, Todd J. , Lipton, Richard B. , Ailani, Jessica

Mayo Clinic

Cephalalgia | September 15, 2021 | Volume: 42 | Issue: 1 | Pages: 3-11

10.1177/03331024211042385 | PMID 34521260 Get It

Background Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist for the preventive treatment of migraine. Methods In the double-blind, phase 3 ADVANCE trial, participants with 4–14 migraine days/month were randomized to atogepant 10 mg, 30 mg, 60 mg, or placebo once daily for 12 weeks. We evaluated the time course of efficacy of atogepant for the preventive treatment of migraine. Analyses included change from baseline in mean monthly migraine days during each of the three 4-week treatment periods, change in weekly migraine days during weeks 1–4, and proportion of participants with a migraine on each day during the first week. Results We analyzed 873 participants (n = 214 atogepant 10 mg, n = 223 atogepant 30 mg, n = 222 atogepant 60 mg, n = 214 placebo). For weeks 1–4, mean change from baseline in mean monthly migraine days ranged from −3.1 to −3.9 across atogepant doses vs −1.6 for placebo ( p < 0.0001). For weeks 5–8 and 9–12, reductions in mean monthly migraine days ranged from −3.7 to −4.2 for atogepant vs −2.9 for placebo ( p ≤ 0.012) and −4.2 to −4.4 for atogepant vs −3.0 for placebo ( p < 0.0002), respectively. Mean change from baseline in weekly migraine days in week 1 ranged from −0.77 to −1.03 for atogepant vs −0.29 with placebo ( p < 0.0001). Percentages of participants reporting a migraine on post-dose day 1 ranged from 10.8% to 14.1% for atogepant vs 25.2% with placebo ( p ≤ 0.0071). Conclusion Atogepant demonstrated treatment benefits as early as the first full day after treatment initiation, and sustained efficacy across each 4-week interval during the 12-week treatment period. Clinical trial registration: ClinicalTrials.gov identifier: NCT03777059
It's in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR T-cell therapy
García-Robledo, Juan Esteban , Knox, Molly G., Goodman, Brent P., Garcia-Robledo, Juan Esteban , Valencia-Sánchez, Cristina , Rosenthal, Allison , Castro, Januario E. , Patel, Bhavesh

Mayo Clinic

No container title available | September 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-859692/v1 Get It

Abstract Usually used in emergency settings, bedside sonographic measurement of optic nerve sheath diameter can aid in diagnosing elevated intracranial pressure. We report a case of a 26-year-old male hospitalized for CAR T-cell therapy with Axicabtagene Ciloleucel for treatment of relapsed diffuse large B-cell lymphoma, who developed progressive symptoms of immune effector cell-associated neurotoxicity syndrome. Fundoscopic examination suggested the presence of blurred optic disc margins. Bedside ocular ultrasound revealed wide optic nerve sheath diameters and bulging optic discs bilaterally. The patient had a ventriculostomy placed for monitoring and received treatment with steroids and mannitol, as well as tocilizumab. After 7 days in the ICU, the patient recovered with no evidence of long-term neurological deficits.
Ibrutinib plus obinutuzumab as frontline therapy for chronic lymphocytic leukemia is associated with a lower rate of infusion-related reactions and with sustained remissions after ibrutinib discontinuation: a single-arm, open-label, phase 1b/2 clinical tri
Lengerke-Diaz, Paula A. , Velez-Lujan, Juliana, Choi, Michale Y., Moreno-Cortes, Eider , Forero-Forero, José Vicente , García-Robledo, Juan Esteban , Jacobs, C , McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Forero, Jose V , Garcia-Robledo, Juan Esteban , Diaz, Paula A Lengerke , Castro, Januario E. , Jacobs, Chaja, Kipps, Thomas J.

Mayo Clinic

No container title available | September 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-887972/v1 Get It

Abstract Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed by single-agent ibrutinib. Patients could discontinue ibrutinib after 36 months with sustained complete response (CR). We evaluated treatment safety, efficacy, and outcomes after ibrutinib discontinuation. The overall response rate was 100%, 28% achieved a CR, and 12.5% achieved bone marrow undetectable minimal residual disease. At a three-year median follow-up, 91% remain in remission with 100% overall survival. Five patients in sustained CR stopped ibrutinib and have not progressed. Eight non-CR patients discontinued for other reasons, with only two progressing. The treatment was safe, with a lower IRR rate. All patients responded to treatment with longer time-to-progression after discontinuation of ibrutinib. Our data support the evaluation of ibrutinib discontinuation strategies in more extensive clinical trials.
Early Diagnosis and Treatment Are Associated With Improved Outcomes in Patients With Multiple Sclerosis
Tobin, W. Oliver , Tobin, W Oliver

Mayo Clinic

Neurology | September 14, 2021 | Volume: 97 | Issue: 17 | Pages: 799-800

10.1212/wnl.0000000000012738 | PMID 34521689 Get It

Trends in outcomes, cost, and readmissions of transcatheter edge to edge repair in the United States (2014–2018)
Sulaiman, Samian , Shaer, Ahmed El , Mayahni, Abdulah Amer, Kawsara, Akram , Osman, Mohammed , El Shaer, Ahmed , Kawsara, Akram , Alkhouli, Mohamad

Mayo Clinic

Catheterization and Cardiovascular Interventions | September 14, 2021 | Volume: 99 | Issue: 3 | Pages: 949-955

10.1002/ccd.29957 | PMID 34520618 Get It

AbstractIntroductionDespite the growth in transcatheter edge‐to‐edge repair (TEER) volume in the United States, data on the temporal changes in procedural outcomes are lacking.MethodsWe utilized the National Readmission Database to assess the annual changes in patient's characteristics, in‐hospital outcomes, cost, and readmissions for patients who underwent TEER between January 1, 2014 and December 31, 2018. Outcomes of interest included mortality, major adverse cardiovascular events (MACE) and any adverse event (AE). We also assessed length of stay and cost.ResultsA total of 22,692 hospitalizations were included. The mean age increased from 75.2 ± 12.9 in 2014 to 78.1 ± 9.8 years in 2018. Changes in the prevalence of risk factors were heterogenous. The incidence of in‐hospital mortality decreased from 4.0% in 2014 to 2.0% in 2018. Both MACE and any AE decreased significantly. Although the incidence of 30‐day readmission remained stable, there was a trend towards a temporal increase in both 90‐day and 180‐day. The adjusted median length of stay of the index admission decreased by 50% and this trend was associated with a $2100 reduction in risk and inflation adjusted in‐hospital cost, however, this reduction was offset by the increased total cost of readmissions within the first 6 months resulting in similar net‐cost.ConclusionThe volume of TEER has grown substantially between 2014 and 2018 coupled with a temporal improvement in in‐hospital outcomes and reduction in cost and length of stay. Re‐hospitalization rates after TEER remained steady at 30‐day and trended towards worsening overtime at 90‐ and 180‐days.
Disease Severity Scoring for COVID-19: A Welcome Semiquantitative Role for Chest Radiography
Little, Brent P. , Little, Brent P

Mayo Clinic

Radiology | September 14, 2021 | Volume: 302 | Issue: 2 | Pages: 470-472

10.1148/radiol.2021212212 | PMID 34519581 Get It

Is Medication Adherence Predictive of Cardiovascular Outcomes and Blood Pressure Control? The Systolic Blood Pressure Intervention Trial (SPRINT)
Glasser, Stephen P. , Rocco, Michael V. , Cofield, Stacey S. , Haley, William E. , Goff, David C. , Rocco, Michael V , Vitolins, Mara Z. , Still, Carolyn H.

Mayo Clinic

American Journal of Hypertension | September 14, 2021 | Volume: 35 | Issue: 2 | Pages: 182-191

10.1093/ajh/hpab145 | PMID 34528669 Get It

Abstract BACKGROUND Adherence to study medications is crucial to evaluating treatment effects in clinical trials. To assess whether in the SPRINT trial, adherence and cardiovascular outcomes are associated regardless of intervention assignment. METHODS This study included 9,361 participants aged ≥50 years, recruited from 102 clinics. Participants were randomized to a Standard Treatment Group (targeted systolic blood pressure [SBP] &lt;140 mm Hg) or an Intensive Treatment Group (targeted SBP &lt;120 mm Hg) and followed for incident cardiovascular events until the study was halted early for benefit. The 8-item Morisky Medication Adherence Scale (MMAS-8) was administered at baseline, and at the 12- and 48-month (or close out) visit. RESULTS Adjusting for covariates, there was no association between the baseline 8-item MMAS-8 and the likelihood of the primary composite endpoint, any of the secondary endpoints, or blood pressure (BP) control. Low adherence was associated with a higher body mass index, SBP, diastolic BP, and Patient Health Questionnaire, and high adherence was associated with a higher Montreal Cognitive Assessment. There was no difference in the MMAS-8 over time by treatment arm assignment. For the primary outcome (a composite of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes), baseline odds ratios (95% confidence intervals) for the Low vs. Medium and vs. High; and, for Medium vs. High MMAS-8 were 1.02 (0.82–1.28), 1.07 (0.85–1.34), and 1.05 (0.88–1.250). CONCLUSIONS In SPRINT, medication adherence as measured using the MMAS-8 was not associated with outcomes or BP control.
Maternal serum lipidomics identifies lysophosphatidic acid as a predictor of small for gestational age neonates
Byeon, Seul Kee , Rahman, Sayedur , Hasan, Tarik , Rizvi, Syed Jafar Raza , Madugundu, Anil K. , Ramarajan, Madan Gopal , Jung, Jae Hun , Chowdhury, Nabidul Haque , Ahmed, Salahuddin , Raqib, Rubhana , Piazza, Amy L. , Rinaldo, Piero, Pandey, Akhilesh , Group, AMANHI Bio-banking Study, Rahman, Sayedur , Pandey, Akhilesh , Chowdhury, Nabidul H , Ahmed, Salahuddin , Kim, Kwang Pyo , Piazza, Amy L , Pandey, Akhilesh , Byeon, Seul Kee , Ramarajan, Madan G , Khanam, Rasheda , Kim, Kwang Pyo , Baqui, Abdullah Hel

Mayo Clinic

Molecular Omics | September 14, 2021 | Volume: 17 | Issue: 6 | Pages: 956-966

10.1039/d1mo00131k | PMID 34519752 Get It

Abstract To discover lipidomic alterations during pregnancy in mothers who subsequently delivered small for gestational age (SGA) neonates and identify predictive lipid markers that can help recognize and manage these mothers, we carried out untargeted lipidomics on maternal serum samples collected between 24–28 weeks of gestation. We used a nested case-control study design and serum from mothers who delivered SGA and appropriate for gestational age babies. We applied untargeted lipidomics using mass spectrometry to characterize lipids and discover changes associated with SGA births during pregnancy. Multivariate pattern recognition software Collaborative Laboratory Integrated Reports (CLIR) was used for the post-analytical recognition of range differences in lipid ratios that could differentiate between SGA and control mothers and their integration for complete separation between the two groups. Here, we report changes in lipids from serum collected during pregnancy in mothers who delivered SGA neonates. In contrast to normal pregnancies where lysophosphatidic acid increased over the course of the pregnancy owing to increased activity of lysophospholipase D, we observed a decrease (32%; P = 0.05) of 20:4-lysophosphatidic acid in SGA mothers, which could potentially compromise fetal growth and development. Integration of lipid ratios in an interpretive tool (CLIR) could completely separate SGA mothers from controls demonstrating the power of untargeted lipidomic analyses for identifying novel predictive biomarkers. Additional studies are required for further assessment of the lipid biomarkers identified in this report.